LuMind RDS Foundation and IDSC Collaborate on a Research and Medical Care Facebook Group for Caregivers

Categories: Blog, Media, News, Other
BURLINGTON, Mass. January 18, 2019 – LuMind™ Research Down Syndrome Foundation (LuMind RDS) and International Down Syndrome Community (IDSC) are combining resources and expertise on a collaboration to create the IDSC LuMind RDS Facebook Group to better serve people with Down syndrome and their communities. “An important part of the LuMind RDS mission is connecting …

Read More

John’s Crazy Socks Supports LuMind RDS with Alzheimer’s “Forget Me Not” Socks

Categories: Blog, News, Other
Giving back is not new to John’s Crazy Socks (JCS), who just announced they are donating $2 from every sale of their Alzheimer’s Awareness Forget Me Not socks to the LuMind RDS Foundation.  They already donate 5 percent of their earnings to Special Olympics and support other causes by creating awareness socks to benefit them. These …

Read More

LuMind Research Down Syndrome Foundation Appoints James Hendrix, Ph.D. as Chief Scientific Officer

Categories: Blog, News, Other
BURLINGTON, Mass. November 1, 2018 – LuMind™ Research Down Syndrome Foundation (LuMind RDS), a non-profit aimed at improving health and independence through high-impact research, today announced the appointment of James Hendrix, Ph.D., as chief scientific officer (CSO). Dr. Hendrix brings more than two decades of industry and non-profit experience in the life sciences, with a …

Read More

LuMind Research Down Syndrome Foundation Launches the Down Syndrome Clinical Trials Network

Categories: News, Other
BURLINGTON, Mass.  [November 1], 2018 – With a combined $3M commitment from the Alana Foundation and biopharmaceutical companies H. Lundbeck A/S and AC Immune SA, the LuMind Research Down Syndrome Foundation (LuMind RDS) is launching the Down Syndrome Clinical Trial Network (DS-CTN) across several sites in the United States. LuMind RDS issued awards to the …

Read More

Published results on the Roche Clinical Trials for CLEMATIS expected in the first half of 2019

Categories: Blog, News, Other
Official LuMind RDS Announcement Many of you have asked LuMind RDS about the publishing of the results of the Hoffman-La Roche (Roche) trials that took place from 2011 to 2016 with their GABA-A targeting molecule basmisanil (RG1662) tested for improving cognition in people with Down syndrome. As you may know, Roche first conducted a small 35-person Phase …

Read More